About

Will Rosellini is the President of CytoImmune Therapeutics, a clinical stage biotechnology company. Previously, he was Chief Executive Officer of Perimeter Medical and, prior to that, Chief Executive Officer of Nexeon Medsystems, a medical device manufacturing company that went public in 2017.

Before that he founded, raised US$16 million across A/B rounds and led Lexington Technology Group, a database company commercialising an electronic health record (EHR) database solution. Before that he founded Sarif Biomedical, a stereotactic cancer microsurgery with IP spun-out of Medtronic. Rosellini completed two acquisitions to form Telemend Medical, Inc. a clinical engineering services company. Rosellini was also Chief Executive Officer at Microtransponder, an implantable neurostimulation developer with solutions for stroke rehabilitation.

He is a former minor league baseball pitcher with the Diamondbacks of the Arizona League, holds a JD, MBA, MS of Accounting, MS of Computational Biology, MS of Neuroscience and MS of Regulatory Science.

Contributions

CONNECTIVITY

DATA IS DRIVING THE FUTURE OF NEUROTECHNOLOGY WITH CRANIALCLOUD

Will Rosellini, Nexeon Medsystems, and Pierre-Francois D’Haese, Neurotargeting, discuss the neurotechnology market and how the Internet of Medical Things is creating exciting opportunities in the space. looking specifically at the collaboration centring Nexeon’s Deep Brain Stiumulation technology and Neurotargeting’s CrainialCloud.

More contributions

EXPERT VIEW

IMPLANTS CONNECT PATIENTS FOR BETTER, FASTER, MORE PERSONALISED CARE

Will Rosellini and Beth Rosellini describe the rapidly advancing area of local field potential recording of nervous system activity which has the ability to record patient data directly and has the potential to form highly advanced connected and closed-loop systems.